Report ID: 10352392 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global In-Vitro Diagnostics (IVD) Market Highlights Over 2021 - 2031
The global in-vitro diagnostics (IVD) market is estimated to garner a revenue of USD 135167.7 Million by the end of 2031 by growing at a CAGR of 4.6% over the forecast period, i.e., 2022 – 2031. Moreover, in 2021, the market generated a revenue of USD 87236.4 Million. The growth of the market can be attributed to the rising incidences of chronic diseases as well as different types of infectious diseases, such as SARS-CoV2, HIV, AIDS, tuberculosis, and pneumonia among others, and therefore the need for diagnostic procedures that can help treat these diseases. According to the statistics by the World Health Organization (WHO), more than 15 million people between the ages of 30 and 69 years are known to die each year from non-communicable diseases (NCD). In addition to this, the rising cases of the COVID-19 pandemic, which according to the WHO reported 515192979 confirmed cases and 6254140 deaths as of 5:13pm (CEST), 9 May 2022, which has driven the need for IVD kits and reagents for the accurate and rapid diagnosis of the viral infection are also anticipated to contribute to the market growth.
-Market.jpg )
GET A SAMPLE COPY OF THIS REPORT
The growth of the market can also be attributed to the rising healthcare expenditure globally and the surge in research and developments in the field of medical sciences. Additionally, the shift in preferences towards point-of-care (PoC) diagnosis over conventional diagnosis procedures, backed by numerous benefits of PoC diagnosis, such as convenience of use, low operational costs and quick analytical results, are also expected to boost the market growth in the coming years.
Global In-Vitro Diagnostics (IVD) Market Regional Synopsis
Regionally, the global in-vitro diagnostics (IVD) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in North America is projected to garner the largest revenue of USD 57175.9 Million by the end of 2031, up from a revenue of USD 36988.2 Million in the year 2021. The growth of the market in the region can primarily be attributed to the presence of a strong healthcare network in the region, rising awareness for in-vitro diagnostics among the individuals as well as healthcare service operators, along with the surge in concern for different types of chronic diseases in the region, especially in the United States. According to the statistics by the Centers for Disease Control and Prevention (CDC), out of 10 adults, 6 adults were known to have a chronic disease in the United States. Furthermore, out of 10 adults, 4 adults were known to have at least 2 or more such diseases in the nation.
On the other hand, the market in Europe is projected to garner the second-largest revenue of USD 36508.8 Million by the end of 2031, up from a revenue of USD 23292.1 Million in the year 2021. The market in the region is further segmented by country into Germany, United Kingdom, France, Italy, Spain, Russia, and the Rest of Europe. The market in Germany is projected to garner the second largest revenue of USD 9017.7 Million by the end of 2031, up from a revenue of USD 5613.4 Million in the year 2021.
Growth Drivers and Challenges Impacting the Growth of the Global In-Vitro Diagnostics (IVD) Market
Growth Drivers
-
Increasing Incidences of Chronic Diseases and Infectious Diseases
-
Surge in Healthcare Expenditure
-
Shift Towards Point-of-Care Diagnosis
Challenges
-
Operational Barriers Faced During Conduction of Diagnostic Tests
-
Dynamic Regulatory Landscape
Global In-Vitro Diagnostics (IVD) Market Segmentation Synopsis
The global in-vitro diagnostics (IVD) market is segmented by product into reagents, instruments, and services. Out of these, the reagents segment is projected to garner the largest revenue of USD 112156.4 Million by the end of 2031, up from a revenue of USD 71786.2 Million in the year 2021. By technology, the market is segmented into immunoassay systems, DNA analytics/sequencing, molecular diagnostics, hematology, tissue diagnostics, microbiology, and others. Out of these, the immunoassay systems segment is projected to garner the largest revenue of USD 39262.8 Million by the end of 2031, up from a revenue of USD 24754.4 Million in the year 2021. By application, the market is segmented into oncology, cardiology, autoimmune diseases, neurology, infectious diseases, gastroenterology, and others. Out of these, the infectious diseases segment is projected to garner the largest revenue of USD 33944.8 Million by the end of 2031, up from a revenue of USD 21378.2 Million in the year 2021. By end-user, the market is segmented into hospitals & clinics, research institutes, diagnostics laboratories, and others. Out of these, the hospitals & clinics segment is projected to garner the largest revenue of USD 64709.2 Million by the end of 2031, up from a revenue of USD 42162.6 Million in the year 2021.
Key Companies Dominating the Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global in-vitro diagnostics (IVD) market that are included in our report are Abbott, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Sysmex Corporation, Qiagen GmbH, bioMerieux SA, Danaher Corporation, Bio Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Exact Sciences Corporation, Becton, Dickinson and Company, and others.
Latest Developments in the Global In-Vitro Diagnostics (IVD) Market:
-
March 30th, 2021: Becton, Dickinson and Company announced that it has received emergency use authorization (EUA) by the United States Food and Drug Administration (FDA) for its BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B, a new rapid antigen test that can detect SARS-CoV-2, influenza A and influenza B in a single test.
-
December 23rd, 2020: Sysmex Corporation announced that it has received marketing approval for the HISCL IFN-λ3 Assay Kit. This test kit is designed in determining the exacerbation risk in positive patients of SARS-CoV-2.
Key Reasons to Buy Our Report
-
The report covers detailed analysis comprising market share attained by each market segment and its sub-segments.
-
It covers market dynamics including growth drivers, trends, potential opportunities, price trend analysis and challenges that impact the market growth.
-
The report includes detailed company profiles of the major players dominating the market.
-
We use effective research methodologies to calculate the market numbers and provide value-added assessment for overall growth.
-
We provide customized reports as per the clients’ requirement helping them to see possible and unexpected challenges and unforeseen opportunities in order to help them reach their goal.
1. Market Definition
2. Assumptions & Acronyms
3. Research Methodology
4. Executive Summary
5. Market Dynamics
6. Value Chain Analysis
7. Regulatory & Standards Landscape
8. Industry Risk Analysis
9. Pricing Analysis by Product
10. Impact of COVID-19 on the Global In-Vitro Diagnostics (IVD) Market
11. Patent Analysis
12.Analysis on End-User of Global In-Vitro Diagnostics (IVD) Market
13.Investment Analysis
14.Industry Growth Outlook
15. Competitive Feature Analysis
16.Competitive Landscape
16.1. Market Share Analysis, 2021
16.2. Company Names
16.2.1. Abbott
16.2.1.1. Detailed Overview
16.2.1.2. Assessment of Key Offering
16.2.1.3. Predictive Strategies & Positioning vs. Current Positioning
16.2.1.4. Analysis on Growth Strategies
16.2.1.5. Exhaustive Analysis on Key Financial Indicators
16.2.1.6. Recent Developments
16.2.2. Siemens Healthcare GmbH
16.2.3. F. Hoffmann-La Roche Ltd.
16.2.4. Eisai Co., Ltd.
16.2.5. Kyowa Kirin Co., Ltd.
16.2.6. Sysmex Corporation
16.2.7. Qiagen GmbH
16.2.8. bioMerieux SA
16.2.9. Danaher Corporation
16.2.10. Bio Rad Laboratories, Inc.
16.2.11. Thermo Fisher Scientific Inc.
16.2.12. Exact Sciences Corporation
16.2.13. Becton, Dickinson and Company
17. Global In-Vitro Diagnostics (IVD) Market
17.1. Market Overview
17.2. By Value (USD Million)
17.3. Market Segmentation Analysis 2021-2031
17.3.1. By Product
17.3.1.1. Reagents & Kits
17.3.1.2. Instruments
17.3.1.2.1. Semi-Automated Instruments
17.3.1.2.2. Fully Automated Instruments
17.3.1.3. Services
17.3.2. By Technology
17.3.2.1. Immunoassay Systems
17.3.2.2. DNA Analytics/Sequencing
17.3.2.3. Molecular Diagnostics
17.3.2.4. Hematology
17.3.2.5. Tissue Diagnostics
17.3.2.6. Microbiology
17.3.2.7. Others
17.3.3. By Application
17.3.3.1. Oncology
17.3.3.2. Cardiology
17.3.3.3. Autoimmune Diseases
17.3.3.4. Neurology
17.3.3.5. Infectious Diseases
17.3.3.6. Gastroenterology
17.3.3.7. Others
17.3.4. By End-User
17.3.4.1. Hospitals & Clinics
17.3.4.2. Research Institutes
17.3.4.3. Diagnostics Laboratories
17.3.4.4. Others
17.3.5. By Region
17.3.5.1. North America
17.3.5.2. Europe
17.3.5.3. Asia Pacific
17.3.5.4. Latin America
17.3.5.5. Middle East & Africa
18.North America In-Vitro Diagnostics (IVD) Market
18.1. Market Overview
18.2. By Value (USD Million)
18.3. Market Segmentation Analysis 2021-2031
18.3.1. By Product
18.3.1.1. Reagents & Kits
18.3.1.2. Instruments
18.3.1.2.1. Semi-Automated Instruments
18.3.1.2.2. Fully Automated Instruments
18.3.1.3. Services
18.3.2. By Technology
18.3.2.1. Immunoassay Systems
18.3.2.2. DNA Analytics/Sequencing
18.3.2.3. Molecular Diagnostics
18.3.2.4. Hematology
18.3.2.5. Tissue Diagnostics
18.3.2.6. Microbiology
18.3.2.7. Others
18.3.3. By Application
18.3.3.1. Oncology
18.3.3.2. Cardiology
18.3.3.3. Autoimmune Diseases
18.3.3.4. Neurology
18.3.3.5. Infectious Diseases
18.3.3.6. Gastroenterology
18.3.3.7. Others
18.3.4. By End-User
18.3.4.1. Hospitals & Clinics
18.3.4.2. Research Institutes
18.3.4.3. Diagnostics Laboratories
18.3.4.4. Others
18.3.5. By Country
18.3.5.1. United States
18.3.5.2. Canada
19.Europe In-Vitro Diagnostics (IVD) Market
19.1. Market Overview
19.2. By Value (USD Million)
19.3. Market Segmentation Analysis 2021-2031
19.3.1. By Product
19.3.2. By Technology
19.3.3. By Application
19.3.4. By End-User
19.3.5. By Country
19.3.5.1. Germany
19.3.5.2. United Kingdom
19.3.5.3. France
19.3.5.4. Italy
19.3.5.5. Spain
19.3.5.6. Russia
19.3.5.7. Rest of Europe
20. Asia Pacific In-Vitro Diagnostics (IVD) Market
20.1. Market Overview
20.2. By Value (USD Million)
20.3. Market Segmentation Analysis 2021-2031
20.3.1. By Product
20.3.2. By Technology
20.3.3. By Application
20.3.4. By End-User
20.3.5. By Country
20.3.5.1. China
20.3.5.2. Japan
20.3.5.3. South Korea
20.3.5.4. Australia
20.3.5.5. India
20.3.5.6. Singapore
20.3.5.7. Rest of APAC
21.Latin America In-Vitro Diagnostics (IVD) Market
21.1. Market Overview
21.2. By Value (USD Million)
21.3. Market Segmentation Analysis 2021-2031
21.3.1. By Product
21.3.2. By Technology
21.3.3. By Application
21.3.4. By End-User
21.3.5. By Country
21.3.5.1. Brazil
21.3.5.2. Argentina
21.3.5.3. Mexico
21.3.5.4. Rest of Latin America
22. Middle East & Africa In-Vitro Diagnostics (IVD) Market
22.1. Market Overview
22.2. By Value (USD Million)
22.3. Market Segmentation Analysis 2021-2031
22.3.1. By Product
22.3.2. By Technology
22.3.3. By Application
22.3.4. By End-User
22.3.5. By Country
22.3.5.1. GCC
22.3.5.2. Israel
22.3.5.3. South Africa
22.3.5.4. Rest of Middle East & Africa
Frequently Asked Question
The market is segmented by product, technology, application, end-user, and by region.
The reagents segment is projected to garner the largest revenue of USD 112156.4 Million by the end of 2031 and display significant growth opportunities.
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10352392 |
Published Date: 21 Mar 2025 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
